Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A

Circulation

Volumn 97, Issue 11, 1998, Pages 1037-1041

  Doggen, Carine J M ^b   Cats, Volkert Manger ^b   Bertina, Rogier M ^b   Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Coagulation; Genetics; Myocardial infarction; Risk factors; Thrombosis

Indexed keywords

PROTHROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CONTROLLED STUDY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

EID: 0032562254     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.11.1037     Document Type: Article

References (14)

1. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
2. Rosendaal FR, Siscovick DS, Schwarts SM, Psaty BM, Raghunatahan TE, Vos HL. A common prothrombin variant (20210G to to A) increases the risk of mycocardial infarction in young women. Blood. 1997;90:1747-1750.
3. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (Resistance to activated protein C) increases the risk of myocardial infarcation in young women. Blood. 1997;89:2817-2821.
4. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA form human nucleated cells. Nudeic Acids Res. 1998;16:1215.
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
6. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251-253.
7. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Br J Haematol. 1997;98:353-355.
8. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210A alllele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78:990-992.
9. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
10. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein in C resistance). Blood. 1995;85:1504-1508.
11. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
12. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. In press.
13. Leitch JW, Birbara T, Freedman B, Wilcox I, Harris PJ. Factors infuencing the time from onset of chest pain to arrival at hospital. Med J Aust. 1989;150:6-10.
14. Lee KL, Woodleif LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, van de Werf F, Califf RM. Predictiors of 30-day mortality in the era of reperfusion for acute mycardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.